OR-004

OR-004 is a preclinical therapeutic candidate being developed by OccamzRazor for the treatment of Parkinson's disease. Discovered using the company's AI-driven platform, the drug is designed to address the complex, multi-factorial nature of Parkinson's by targeting several key pathological mechanisms simultaneously, including chromatin regulation, mitochondrial health, lysosomal function, and sphingolipid metabolism. OR-004 is specifically intended for patient subgroups categorized by their age of onset and medical history, representing a precision medicine approach to neurodegeneration. The program aims to mitigate oxidative stress and prevent the death of dopaminergic neurons.